Literature DB >> 22135002

NDRG2 down-regulation and CD24 up-regulation promote tumor aggravation and poor survival in patients with gallbladder carcinoma.

Shi-peng Song1, Sheng-bin Zhang, Rui Liu, Li Yao, Yu-qin Hao, Ming-mei Liao, Yang-de Zhang, Zhe-hai Li.   

Abstract

Recent studies have demonstrated that N-Myc downstream-regulated gene 2 (NDRG2) may reduce the metastatic potential of breast cancer and hepatocellular carcinoma cells by regulating the expression of CD24, which is expressed in a large variety of solid tumors. The aim of this study was to clarify the clinical value of NDRG2 and CD24 expression in primary gallbladder carcinoma (GBC). One hundred and thirty GBC tissues were evaluated by immunohistochemistry for NDRG2 and CD24 expression. The associations of NDRG2 and CD24 expression with the clinicopathological characteristics and the overall survival of patients with GBC were analyzed. NDRG2 and CD24 were positively expressed in 49/130 (37.69%) and 107/130 (82.31%) of GBC tissues, respectively. In addition, the tumors with the down-regulation of NDRG2 and the up-regulation of CD24 more frequently had lymph node metastasis and lymphovascular invasion. Moreover, the tumors with the down-regulation of NDRG2 and the up-regulation of CD24 tended to show deeper invasion depth and higher TNM stage. There was a negative correlation between NDRG2 expression and CD24 expression in GBC tissues (r = -0.86, P < 0.001). The patients with NDRG2 negative expression correlated with poor prognosis of GBC (P = 0.01), as opposed to CD24 (P = 0.01). The survival rate of the patients with NDRG2-/CD24+ expression was the lowest (P < 0.001), and conjoined expression of NDRG2-/CD24+ was an independent prognostic indicator of GBC (P = 0.003). Our data suggest that NDRG2 down-regulation or CD24 up-regulation is an important feature of GBC. A combined detection of NDRG2/CD24 co-expression may benefit us in prediction of the prognosis in GBC.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22135002     DOI: 10.1007/s12032-011-0110-y

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  21 in total

1.  Analysis of the influence of two CD24 genetic variants in Crohn's disease and ulcerative colitis.

Authors:  Lina-Marcela Diaz-Gallo; Luz María Medrano; María Gómez-García; Carlos Cardeña; Luis Rodrigo; Juan Luis Mendoza; Carlos Taxonera; Antonio Nieto; Guillermo Alcain; Ignacio Cueto; Miguel A López-Nevot; Elena Urcelay; Javier Martin
Journal:  Hum Immunol       Date:  2011-06-17       Impact factor: 2.850

2.  CD24 offers a therapeutic target for control of bladder cancer metastasis based on a requirement for lung colonization.

Authors:  Jonathan B Overdevest; Shibu Thomas; Glen Kristiansen; Donna E Hansel; Steven C Smith; Dan Theodorescu
Journal:  Cancer Res       Date:  2011-04-11       Impact factor: 12.701

Review 3.  Carcinoma of the gallbladder.

Authors:  Sanjeev Misra; Arun Chaturvedi; Naresh C Misra; Indra D Sharma
Journal:  Lancet Oncol       Date:  2003-03       Impact factor: 41.316

4.  Clinicopathologic and prognostic significance of CD24 in gallbladder carcinoma.

Authors:  Bo Liu; Yangde Zhang; Mingmei Liao; Zhansheng Deng; Liansheng Gong; Jiarui Jiang; Ling Lynn; Kai Wu; Xiongying Miao
Journal:  Pathol Oncol Res       Date:  2010-06-22       Impact factor: 3.201

5.  The role of CD24 in various human epithelial neoplasias.

Authors:  Sung-Chul Lim; Seon-Hee Oh
Journal:  Pathol Res Pract       Date:  2005       Impact factor: 3.250

6.  NDRG2 expression regulates CD24 and metastatic potential of breast cancer cells.

Authors:  Jin Zheng; Qiang Liu; Yan Li; Jiandong Yang; Ji Ma; Fang Yu; Hengjun Shi; Qinyou Ren; Rui Zhang; Jin Zhang; Yan Xue; Yurong Tao; Ning Jiang; Hang Guo; LiBo Yao; Wenchao Liu
Journal:  Asian Pac J Cancer Prev       Date:  2010

7.  Expression of hypoxia-inducible factor-1 alpha (HIF-1alpha) in patients with the gallbladder carcinoma.

Authors:  Erdenebulgan Batmunkh; Mitsuo Shimada; Yuji Morine; Satoru Imura; Hirofumi Kanemura; Yusuke Arakawa; Jun Hanaoka; Mami Kanamoto; Koji Sugimoto; Masaaki Nishi
Journal:  Int J Clin Oncol       Date:  2010-02       Impact factor: 3.402

8.  N-Myc downstream-regulated gene 2 (NDRG2) inhibits glioblastoma cell proliferation.

Authors:  Yanchun Deng; Libo Yao; Ling Chau; Samuel Sai-ming Ng; Ying Peng; Xinping Liu; Wo-shing Au; Jicun Wang; Fuyang Li; Shaoping Ji; Hua Han; Xiaoyan Nie; Qing Li; Hsiang-fu Kung; Suet-yi Leung; Marie Chia-mi Lin
Journal:  Int J Cancer       Date:  2003-09-01       Impact factor: 7.396

9.  Overexpression of epithelial cell adhesion molecule antigen in gallbladder carcinoma is an independent marker for poor survival.

Authors:  Meri Varga; Peter Obrist; Stephan Schneeberger; Gilbert Mühlmann; Christina Felgel-Farnholz; Dominic Fong; Mathias Zitt; Thomas Brunhuber; Georg Schäfer; Guenther Gastl; Gilbert Spizzo
Journal:  Clin Cancer Res       Date:  2004-05-01       Impact factor: 12.531

10.  Aggressive surgical approach for stage IV gallbladder carcinoma based on Japanese Society of Biliary Surgery classification.

Authors:  Hiroaki Shimizu; Fumio Kimura; Hiroyuki Yoshidome; Masayuki Ohtsuka; Atsushi Kato; Hideaki Yoshitomi; Satoshi Nozawa; Katunori Furukawa; Noboru Mitsuhashi; Dan Takeuchi; Kosuke Suda; Isaku Yoshioka; Masaru Miyazaki
Journal:  J Hepatobiliary Pancreat Surg       Date:  2007-07-30
View more
  11 in total

1.  Increased expression of CD24 is associated with tumor progression and prognosis in patients suffering osteosarcoma.

Authors:  J Tang; H Cai; L Lin; P Xie; W Zhong; M Tang
Journal:  Clin Transl Oncol       Date:  2012-11-10       Impact factor: 3.405

2.  FXR controls the tumor suppressor NDRG2 and FXR agonists reduce liver tumor growth and metastasis in an orthotopic mouse xenograft model.

Authors:  Ulrich Deuschle; Julia Schüler; Andreas Schulz; Thomas Schlüter; Olaf Kinzel; Ulrich Abel; Claus Kremoser
Journal:  PLoS One       Date:  2012-10-09       Impact factor: 3.240

3.  Downregulation of CD99 and upregulation of human leukocyte antigen class II promote tumor aggravation and poor survival in patients with osteosarcomas.

Authors:  Quan Zhou; Jin Xu; Jiali Zhao; Shaoxian Zhang; Wei Pan
Journal:  Onco Targets Ther       Date:  2014-03-24       Impact factor: 4.147

4.  Glioma Malignancy-Dependent NDRG2 Gene Methylation and Downregulation Correlates with Poor Patient Outcome.

Authors:  Daina Skiriutė; Giedrius Steponaitis; Paulina Vaitkienė; Mykolas Mikučiūnas; Kęstutis Skauminas; Arimantas Tamašauskas; Arunas Kazlauskas
Journal:  J Cancer       Date:  2014-05-13       Impact factor: 4.207

5.  Abundant NDRG2 Expression Is Associated with Aggressiveness and Unfavorable Patients' Outcome in Basal-Like Breast Cancer.

Authors:  Vera Kloten; Martin Schlensog; Julian Eschenbruch; Janina Gasthaus; Janina Tiedemann; Jolein Mijnes; Timon Heide; Till Braunschweig; Ruth Knüchel; Edgar Dahl
Journal:  PLoS One       Date:  2016-07-11       Impact factor: 3.240

Review 6.  Gallbladder cancer epidemiology, pathogenesis and molecular genetics: Recent update.

Authors:  Aarti Sharma; Kiran Lata Sharma; Annapurna Gupta; Alka Yadav; Ashok Kumar
Journal:  World J Gastroenterol       Date:  2017-06-14       Impact factor: 5.742

7.  Expression of N-Myc Downstream-Regulated Gene 2 in Bladder Cancer and Its Potential Utility as a Urinary Diagnostic Biomarker.

Authors:  Miao Zhang; Bo Ren; Zhi Li; Wenyan Niu; Yueling Wang
Journal:  Med Sci Monit       Date:  2017-09-27

8.  Membranous CD24 expression as detected by the monoclonal antibody SWA11 is a prognostic marker in non-small cell lung cancer patients.

Authors:  Michael Majores; Anne Schindler; Angela Fuchs; Johannes Stein; Lukas Heukamp; Peter Altevogt; Glen Kristiansen
Journal:  BMC Clin Pathol       Date:  2015-11-16

Review 9.  Emerging role of N-myc downstream-regulated gene 2 (NDRG2) in cancer.

Authors:  Wei Hu; Chongxi Fan; Peng Jiang; Zhiqiang Ma; Xiaolong Yan; Shouyin Di; Shuai Jiang; Tian Li; Yedong Cheng; Yang Yang
Journal:  Oncotarget       Date:  2016-01-05

10.  Low NDRG2 expression predicts poor prognosis in solid tumors: A meta-analysis of cohort study.

Authors:  Aiqin Gu; Jie Xu; Jun Ye; Chuanmeng Zhang
Journal:  Medicine (Baltimore)       Date:  2020-10-09       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.